Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
Heinz Ludwig,
Bela Hausmann,
Martin Schreder,
Wolfram Pönisch,
Niklas Zojer,
Stefan Knop,
Eberhard Gunsilius,
Alexander Egle,
Andreas Petzer,
Hermann Einsele,
Roman Hajek,
Katja Weisel,
Karl Jochen Krenosz,
Alois Lang,
Daniel Lechner,
Richard Greil,
David Berry
Affiliations
Heinz Ludwig
Wilhelminen Cancer Research Institute Vienna Austria
Bela Hausmann
Joint Microbiome Facility (JMF) Medical University of Vienna & University of Vienna Vienna Austria
Martin Schreder
Division of Hematology and Medical Oncology Department of Internal Medicine II Würzburg University Medical Center Würzburg Germany
Wolfram Pönisch
Department of Hematology University of Leipzig Leipzig Germany
Niklas Zojer
Department of Medicine I Wilhelminenspital Vienna Austria
Stefan Knop
Division of Hematology and Medical Oncology Department of Internal Medicine II Würzburg University Medical Center Würzburg Germany
Eberhard Gunsilius
Department of Internal Medicine V Medical University Innsbruck Innsbruck Austria
Alexander Egle
Department of Internal Medicine III with Haematology Medical Oncology, Hemostaseology Infectiology and Rheumatology Oncologic Center Salzburg Cancer Research Institute ‐ Laboratory for Immunological and Molecular Cancer Research (SCRI‐LIMCR) Paracelsus Medical University Cancer Cluster Salzburg Salzburg Austria
Andreas Petzer
Department of Internal Medicine I Ordensklinikum Linz BHS‐EKH, Linz Linz Austria
Hermann Einsele
Division of Hematology and Medical Oncology Department of Internal Medicine II Würzburg University Medical Center Würzburg Germany
Roman Hajek
Department of Hematooncology University Hospital Ostrava Ostrava Czech Republic
Katja Weisel
University of Tübingen Tübingen Germany
Karl Jochen Krenosz
Department of Internal Medicine 3 Kepler Universitätsklinikum GmbH Med Campus III Linz Austria
Alois Lang
Innere Medizin II LKH Feldkirch Feldkirch Austria
Daniel Lechner
Department of Medicine I ‐ Hematology with Stem Cell Transplantation Hemostaseology and Medical Oncology Ordensklinikum Linz Elisabethinen Linz Austria
Richard Greil
Department of Internal Medicine III with Haematology Medical Oncology, Hemostaseology Infectiology and Rheumatology Oncologic Center Salzburg Cancer Research Institute ‐ Laboratory for Immunological and Molecular Cancer Research (SCRI‐LIMCR) Paracelsus Medical University Cancer Cluster Salzburg Salzburg Austria
David Berry
Joint Microbiome Facility (JMF) Medical University of Vienna & University of Vienna Vienna Austria
Abstract Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib‐thalidomide‐dexamethasone. Increased alpha diversity (Shannon index) at the phylum level was associated with longer progression‐free survival (PFS) (10.2 vs 8.5 months, P = .04), particularly in patients with very long (>75% quartile) PFS . Additionally, alpha diversity was lower in patients with progressive disease (P < .05). These findings suggest an interrelationship between the oral microbiome and outcome in patients with MM and encourage a novel direction for diagnostic and/or therapeutic strategies.
